Tampere University of Technology

TUTCRIS Research Portal

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

Research output: Contribution to journalArticleScientificpeer-review

Standard

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. / Egerdie, R. B.; Saad, F.; Smith, M. R.; Tammela, T. L J; Heracek, J.; Sieber, P.; Ke, C.; Leder, B.; Dansey, R.; Goessl, C.

In: PROSTATE CANCER AND PROSTATIC DISEASES, Vol. 15, No. 3, 09.2012, p. 308-312.

Research output: Contribution to journalArticleScientificpeer-review

Harvard

Egerdie, RB, Saad, F, Smith, MR, Tammela, TLJ, Heracek, J, Sieber, P, Ke, C, Leder, B, Dansey, R & Goessl, C 2012, 'Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer', PROSTATE CANCER AND PROSTATIC DISEASES, vol. 15, no. 3, pp. 308-312. https://doi.org/10.1038/pcan.2012.18

APA

Egerdie, R. B., Saad, F., Smith, M. R., Tammela, T. L. J., Heracek, J., Sieber, P., ... Goessl, C. (2012). Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES, 15(3), 308-312. https://doi.org/10.1038/pcan.2012.18

Vancouver

Egerdie RB, Saad F, Smith MR, Tammela TLJ, Heracek J, Sieber P et al. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. PROSTATE CANCER AND PROSTATIC DISEASES. 2012 Sep;15(3):308-312. https://doi.org/10.1038/pcan.2012.18

Author

Egerdie, R. B. ; Saad, F. ; Smith, M. R. ; Tammela, T. L J ; Heracek, J. ; Sieber, P. ; Ke, C. ; Leder, B. ; Dansey, R. ; Goessl, C. / Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. In: PROSTATE CANCER AND PROSTATIC DISEASES. 2012 ; Vol. 15, No. 3. pp. 308-312.

Bibtex - Download

@article{fed1b7b55acb4b41888ed69cc9ec77ac,
title = "Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer",
abstract = "Background: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. Methods: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients. Results: At 36 months, significantly more patients in the denosumab arm had increases of >3{\%} BMD from baseline at each site studied compared with placebo (LS, 78 vs 17{\%}; FN, 48 vs 13{\%}; TH, 48 vs 6{\%}; distal 1/3 radius, 40 vs 7{\%} (P",
keywords = "androgen deprivation, antiresorptive therapy, bone loss, bone mineral density, responder analysis",
author = "Egerdie, {R. B.} and F. Saad and Smith, {M. R.} and Tammela, {T. L J} and J. Heracek and P. Sieber and C. Ke and B. Leder and R. Dansey and C. Goessl",
year = "2012",
month = "9",
doi = "10.1038/pcan.2012.18",
language = "English",
volume = "15",
pages = "308--312",
journal = "PROSTATE CANCER AND PROSTATIC DISEASES",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "3",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer

AU - Egerdie, R. B.

AU - Saad, F.

AU - Smith, M. R.

AU - Tammela, T. L J

AU - Heracek, J.

AU - Sieber, P.

AU - Ke, C.

AU - Leder, B.

AU - Dansey, R.

AU - Goessl, C.

PY - 2012/9

Y1 - 2012/9

N2 - Background: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. Methods: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients. Results: At 36 months, significantly more patients in the denosumab arm had increases of >3% BMD from baseline at each site studied compared with placebo (LS, 78 vs 17%; FN, 48 vs 13%; TH, 48 vs 6%; distal 1/3 radius, 40 vs 7% (P

AB - Background: Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. Methods: Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients. Results: At 36 months, significantly more patients in the denosumab arm had increases of >3% BMD from baseline at each site studied compared with placebo (LS, 78 vs 17%; FN, 48 vs 13%; TH, 48 vs 6%; distal 1/3 radius, 40 vs 7% (P

KW - androgen deprivation

KW - antiresorptive therapy

KW - bone loss

KW - bone mineral density

KW - responder analysis

UR - http://www.scopus.com/inward/record.url?scp=84865313354&partnerID=8YFLogxK

U2 - 10.1038/pcan.2012.18

DO - 10.1038/pcan.2012.18

M3 - Article

VL - 15

SP - 308

EP - 312

JO - PROSTATE CANCER AND PROSTATIC DISEASES

JF - PROSTATE CANCER AND PROSTATIC DISEASES

SN - 1365-7852

IS - 3

ER -